Estée Lauder Companies Inc. announced a minority investment in 111SKIN, a luxury clinical skin‑care brand founded by plastic and reconstructive surgeon Dr. Yannis Alexandrides. The deal, announced on April 30, 2026, does not disclose the investment amount or valuation, but it signals a strategic move to deepen the company’s footprint in the high‑margin clinical‑beauty market.
111SKIN, launched in 2012, markets more than 30 products built around its proprietary NAC Y2™ technology, which supports skin repair and maintains a healthy complexion. The brand sells through luxury retailers, e‑commerce, and high‑end spa channels—including Harrods, Bluemercury, Nordstrom, Mandarin Oriental, and Aman—while its direct‑to‑consumer channel accounts for roughly 20% of total sales.
The investment aligns with Estée Lauder’s “Beauty Reimagined” strategy, which seeks to accelerate innovation and deepen consumer engagement through science‑driven products. By bringing 111SKIN’s clinical expertise and advanced actives into its portfolio, Estée Lauder aims to capture a share of the rapidly expanding clinical‑beauty segment and complement existing high‑end brands such as La Mer and Clinique. Dr. Alexandrides will remain involved, preserving the brand’s clinical credibility while leveraging Estée Lauder’s global reach.
Estée Lauder’s recent financial performance underscores the strategic timing of the deal. Net sales rose 4% to $3.5 billion in Q1 FY2026, driven by a 3% increase in organic sales, while Q4 FY2025 saw a 12% decline to $3.41 billion. The company’s Profit Recovery and Growth Plan has helped expand gross margins, and the new investment is positioned to enhance profitability in a high‑margin segment that can offset weaker legacy categories.
Stéphane de La Faverie, Estée Lauder’s President and CEO, said, “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and beauty, as consumers increasingly seek products that deliver visible, treatment‑inspired results. 111Skin exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high‑performance luxury skin care.” Dr. Alexandrides added, “We are thrilled to partner with The Estée Lauder Companies and to unlock an exciting new chapter for 111SKIN.”
The investment positions Estée Lauder to compete more effectively in the luxury clinical‑skincare market, where brands focus on scientific innovation and potent ingredients. While the deal value remains undisclosed, the partnership is expected to accelerate 111SKIN’s global reach and strengthen Estée Lauder’s high‑margin portfolio, reinforcing the company’s broader strategy to restore growth and profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.